bioage labs ipo news - Search News

BioAge, obesity

Fast Company · 5d

BioAge Labs IPO: Stock price will be closely watched today as the obesity drug developer debuts on the Nasdaq

California-based biotech BioAge Labs will have its initial public offering of stock. The company is developing Azelaprag, a weight loss drug.

Seeking Alpha on MSN · 5d

Weight-loss drug developer BioAge Labs aims to raise $198M from U.S. IPO

Weight-loss drug developer BioAge Labs (BIOA) on Wednesday announced the pricing of its upsized initial public offering of 11,000,000 shares of its common stock at a public offering price of $18.00 per share.

Obesity drug developer BioAge Labs aims up to $640 mln valuation in upsized US IPO

BioAge Labs is eyeing a valuation of up to $639.7 million in its upsized initial public offering in the United States, the obesity drug developer said on Wednesday, in a sign of strong demand from investors.

21h

BioAge Labs: Weighing The Risks And Rewards Of A Biotech Revival

Discover the revival of the biotech sector, with IPOs resurging and promising weight loss drug potential, despite facing ...

3don MSN

More Companies Explore Going Public as the IPO Market Shows Signs of Thawing

After BioAge Labs raised nearly $200 million in its IPO this week, several companies are beginning to eye the public markets, ...

FierceBiotech5d

BioAge brings in almost $200M from IPO as obesity biotech joins Nasdaq

BioAge Labs is bringing in almost $200 million via its Nasdaq IPO this morning, with the proceeds earmarked for taking its ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results